Epistem, a UK-based personalised medicine and biotechnology company, says David Budd has been appointed as Chief Executive and as a Director of Epistem. He will join the Manchester firm by the middle of April.
Budd has more than 20 years of international commercial and operational experience in the diagnostics and medical devices field, launching multiple diagnostics products into international markets. He joins the firm from Leica Biosystems, where he was General Manager of Leica Biosystems Amsterdam. He previously served as Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, market research and product launches for diagnostic tests.
Budd's previous roles include point-of-care, molecular, and central laboratory marketing and commercialisation responsibilites as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics.
Ian Gilham will continue to act as interim Chief Executive until Budd joins Epistem.
